Shadia Ibrahim Jalal

机构：Indiana University Health, Indiana Cancer Consortium, Richard L. Roudebush VA Medical Center, Department of Veterans Affairs, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis, Indiana University · ORCID：0000-0001-8938-7077

发表论文 244 篇 · 总被引 9965 次 · h-index 40

代表论文

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology (2025 · Journal of the National Comprehensive Cancer Network · 被引 205)
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081 (2025 · Journal for ImmunoTherapy of Cancer · 被引 10)
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1. (2023 · Journal of Clinical Oncology · 被引 8)
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma (2024 · Frontiers in Oncology · 被引 5)
Evaluating the feasibility and predictive accuracy of biodynamic imaging to platinum-based chemotherapy response in esophageal adenocarcinoma (2024 · Frontiers in Oncology · 被引 4)
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies. (2024 · Journal of Clinical Oncology · 被引 4)